210 related articles for article (PubMed ID: 22367999)
1. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease.
Kachroo A; Schwarzschild MA
Ann Neurol; 2012 Feb; 71(2):278-82. PubMed ID: 22367999
[TBL] [Abstract][Full Text] [Related]
2. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
Xu K; Di Luca DG; Orrú M; Xu Y; Chen JF; Schwarzschild MA
Neuroscience; 2016 May; 322():129-37. PubMed ID: 26905951
[TBL] [Abstract][Full Text] [Related]
4. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
5. Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.
Ferreira DG; Batalha VL; Vicente Miranda H; Coelho JE; Gomes R; Gonçalves FQ; Real JI; Rino J; Albino-Teixeira A; Cunha RA; Outeiro TF; Lopes LV
Cereb Cortex; 2017 Jan; 27(1):718-730. PubMed ID: 26534909
[TBL] [Abstract][Full Text] [Related]
6. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
7. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.
Salamone JD; Collins-Praino LE; Pardo M; Podurgiel SJ; Baqi Y; Müller CE; Schwarzschild MA; Correa M
Eur Neuropsychopharmacol; 2013 Aug; 23(8):972-7. PubMed ID: 22947264
[TBL] [Abstract][Full Text] [Related]
8. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
9. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A
Cai Q; Xu N; He Y; Zhu J; Ye F; Luo Z; Lu R; Huang L; Zhang F; Chen JF; Li Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674880
[TBL] [Abstract][Full Text] [Related]
11. An update on adenosine A2A receptors as drug target in Parkinson's disease.
Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A
Hu Q; Xu L; Liu X; Wang Y; Yuan J
Neurosci Lett; 2024 Mar; 826():137610. PubMed ID: 38157926
[TBL] [Abstract][Full Text] [Related]
13. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism.
Liu Z; Yu Y; Li X; Ross CA; Smith WW
Pharmacol Res; 2011 May; 63(5):439-44. PubMed ID: 21237271
[TBL] [Abstract][Full Text] [Related]
14. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease.
Cai W; Srivastava P; Feng D; Lin Y; Vanderburg CR; Xu Y; Mclean P; Frosch MP; Fisher DE; Schwarzschild MA; Chen X
Mol Neurodegener; 2022 Feb; 17(1):16. PubMed ID: 35197079
[TBL] [Abstract][Full Text] [Related]
15. Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Xiao D; Cassin JJ; Healy B; Burdett TC; Chen JF; Fredholm BB; Schwarzschild MA
Brain Res; 2011 Jan; 1367():310-8. PubMed ID: 20828543
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.
Carta AR; Kachroo A; Schintu N; Xu K; Schwarzschild MA; Wardas J; Morelli M
J Neurochem; 2009 Dec; 111(6):1478-89. PubMed ID: 19817968
[TBL] [Abstract][Full Text] [Related]
17. Targeting the adenosine A
Zhao Y; Zhou YG; Chen JF
Chin J Traumatol; 2024 May; 27(3):125-133. PubMed ID: 37679245
[TBL] [Abstract][Full Text] [Related]
18. A2A receptors in neuroprotection of dopaminergic neurons.
Pedata F; Pugliese AM; Melani A; Gianfriddo M
Neurology; 2003 Dec; 61(11 Suppl 6):S49-50. PubMed ID: 14663010
[No Abstract] [Full Text] [Related]
19. α-Synuclein Selectively Impairs Motor Sequence Learning and Value Sensitivity: Reversal by the Adenosine A2A Receptor Antagonists.
He Y; Huang L; Wang K; Pan X; Cai Q; Zhang F; Yang J; Fang G; Zhao X; You F; Feng Y; Li Y; Chen JF
Cereb Cortex; 2022 Feb; 32(4):808-823. PubMed ID: 34339491
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.
Yu L; Shen HY; Coelho JE; Araújo IM; Huang QY; Day YJ; Rebola N; Canas PM; Rapp EK; Ferrara J; Taylor D; Müller CE; Linden J; Cunha RA; Chen JF
Ann Neurol; 2008 Mar; 63(3):338-46. PubMed ID: 18300283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
